THE FDA DESIGNATED BREAKTHROUGH DEVICE

Detect and monitor brain diseases through typing cadence

Breaking News!

NIDA (The National Institute on Drug Abuse, part of NIH) has awarded a grant to Rutgers University to conduct a five-year research study entitled " Monitoring acute and longer-term effects of cannabis on psychomotor performance in daily life in chronic pain patients." The first-year grant is $450,000.

The study will use a novel psychomotor assay (focusing on cognitive performance) based on natural typing on a personal computer to remotely monitor cannabis-related impairment for which the NeuraMetrix platform will be used.

How do we change the world?

Our Goal is to enable dramatically better care of patients with various neurological diseases or psychiatric disorders by providing researchers and physicians with an exceptionally precise and accurate measurement of brain health.​​​ 

Or, as a leading neuroscientist puts it

"Imprecise, inaccessible, and outdated assessments of cognition dominate the mental health world". - Professor Adam Gazzaley, M.D., University of California San Francisco

From the experts

//

"We have been looking for this for 30 years."


- Dr. Robert W. Mahley, M.D. Ph.D.
Senior Investigator, President Emeritus and Founder, Gladstone Institutes, Senior Investigator, Gladstone Institute of Neurological Disease, Professor of Pathology and Medicine, University of California San Francisco, Chairman, NeuraMetrix’ Scientific Advisory Board
​​​​​​​​​​​​​​
//

"'We need digital biomarker technologies with very strong statistics so we can actually think about not waiting till we are so sick, we need a doctor…."


- Dr. Rhoda, Au PhD
Professor, Boston University, co-PI, Framingham Heart Study Brain Aging Project & Director of Neuropsychology, Director of Global Cohort Development, Davos Alzheimer's Collaborative
​​​​​​​​​​​​​​​​​​​​​
//

"We train our Huntington’s patients intensively. I am amazed that the effects are so clearly shown in the inconsistency scores."


- Dr. Christina Lang, M.D. – Department of Neurology, Universität Ulm, Germany
​​​​​​​
//

"This will revolutionize how we treat these poor patients."


- CTO of major hospital system in Scandinavia
​​​​​​​
//

"NeuraMetrix technology has potential to provide first-in-class early detection of affective disorders potentially fast-tracking diagnosis and reducing burden of illness."


- Dr. Martin Schalling, M.D., Professor of Medical Genetics Karolinska Institutet,  Chair Swedish Mental Health Fund
​​​​​​​
//

"'Digital is the new blood."


- Dr. Rhoda Au, Ph.D.
Professor, Boston University, co-PI, Framingham Heart Study Brain Aging Project & Director of Neuropsychology, Director of Global Cohort Development, Davos Alzheimer's Collaborative
​​​​​​​

Some of our Partners

Boston University School of Medicine LogoBoston University School of Medicine Logo

Upcoming Events

No currently planned upcoming events

Sign up for the NeuraMetrix newsletter